GMP Biotechnology

GMP Biotechnology is a private oncology-focused biotechnology joint venture associated with Oncotelic Therapeutics and Dragon Overseas Capital Limited. The company appears to function as a development and holding vehicle for subsidiaries including Sapu Biosciences and Sapu Nano, supporting clinical development, manufacturing, and commercialization-oriented activities. Its disclosed pipeline centers on OT-101, a Transforming growth factor beta 2-targeting antisense oligonucleotide being advanced for pancreatic cancer and other oncology indications, and Sapu003, an intravenous everolimus product enabled by the Deciparticle nanoparticle delivery platform. Public disclosures also indicate work in COVID-19 and additional undisclosed compounds through the joint venture. Overall, GMP Biotechnology is best characterized as a private, oncology-oriented biotech platform company with subsidiaries spanning RNA therapeutics, formulation innovation, and GMP manufacturing.